IMVT
Immunovant, Inc. · Healthcare · Market cap $5.9B
Insiders sold $1.1M net in the last 90 days ·6 sellers, 0 buyers· 2 of 10 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 9, 2026
Insider Buying
$350.0M
reported purchases (SEC code P)
Insider Selling
$16.3M
reported sales (SEC code S)
Unique Insiders
11
in the rolling window
Latest filing
Oct 9, 2026
Stout Jay S
Immunovant, Inc. (IMVT) has 53 SEC Form 4 filings (91 transaction rows) in the rolling window, disclosed by 11 distinct insiders. Most recent filing: Oct 9, 2026.
Inside the rolling window, 11 insiders at Immunovant, Inc. reported 1 open-market purchase totaling $350.0M and 41 open-market sales totaling $16.3M. The most active filer is Chief Technology Officer Stout Jay S with 9 filings. Insiders have net sold $13.6M over the trailing 6 months. The most recent open-market filing is a sale of 3,809 shares by Chief Technology Officer Stout Jay S, dated Oct 7, 2026, worth $122K.
- Industry:Biotechnology
- CEO:Eric Venker
- Employees:315
- HQ:Durham, NY, US
- IPO:2019-06-21
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Technology Officer | Sale | 3,809 | $122K | Oct 9 | -6.9% | SEC ↗ | |
| Chief Legal Officer | Sale | 1,327 | $43K | Oct 9 | -6.9% | SEC ↗ | |
| Chief Operating Officer | Sale | 2,241 | $72K | Oct 9 | -6.9% | SEC ↗ | |
| Chief Executive Officer | Sale | 3,506 | $120K | Oct 5 | -14.6% | SEC ↗ | |
| Chief Legal Officer | Sale | 2,846 | $103K | Sep 25 | -14.8% | SEC ↗ | |
| Director | Sale | 1,500 | $65K | Aug 28 | -31.1% | SEC ↗ | |
| Chief Operating Officer | Sale | 3,056 | $135K | Aug 21 | -36.0% | SEC ↗ | |
| Director | Sale | 1,500 | $60K | Jul 24 | -29.2% | SEC ↗ | |
| Chief Financial Officer | Sale | 6,798 | $263K | Jul 24 | -29.2% | SEC ↗ | |
| Chief Technology Officer | Sale | 2,857 | $111K | Jul 24 | — | SEC ↗ | |
| Chief Technology Officer | Sale | 3,487 | $138K | Jul 10 | — | SEC ↗ | |
| Chief Legal Officer | Sale | 1,206 | $48K | Jul 10 | — | SEC ↗ | |
| Chief Operating Officer | Sale | 2,036 | $81K | Jul 10 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 3,092 | $119K | Jul 6 | — | SEC ↗ | |
| Chief Operating Officer | Sale | 17,714 | $679K | Jun 26 | — | SEC ↗ | |
| Chief Technology Officer | Sale | 40,000 | $1.5M | Jun 26 | — | SEC ↗ | |
| Chief Legal Officer | Sale | 17,824 | $683K | Jun 26 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 10,000 | $385K | Jun 26 | — | SEC ↗ | |
| Director | Sale | 1,500 | $57K | Jun 26 | — | SEC ↗ | |
| Chief Legal Officer | Sale | 2,634 | $93K | Jun 22 | — | SEC ↗ | |
| Director | Sale | 1,500 | $51K | Jun 16 | — | SEC ↗ | |
Fromkin Andrew J.First in 6 months | Director | Sale | 221,951 | $7.4M | May 29 | — | SEC ↗ |
| Chief Operating Officer | Sale | 3,115 | $101K | May 22 | — | SEC ↗ | |
Pande AtulFirst filing | Director | Sale | 6,000 | $192K | May 21 | — | SEC ↗ |
Susman Robert GrahamFirst filing | Director | Sale | 2,502 | $68K | May 1 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does IMVT have?
Immunovant, Inc. (IMVT) has 53 SEC Form 4 filings (91 transaction rows) in the rolling 365-day window, disclosed by 11 distinct insiders. Most recent filing: Oct 9, 2026.
When was the most recent SEC Form 4 filing for IMVT?
The most recent Form 4 filing for IMVT on Tracefour is dated Oct 9, 2026.
Who is the most active insider at IMVT?
The most active SEC Form 4 filer at IMVT in the rolling window is Chief Technology Officer Stout Jay S, with 9 filings.
What is the net insider flow at IMVT over the last 6 months?
Over the trailing 180 days, insiders at IMVT have net sold $13.6M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at IMVT in the current window?
Inside the rolling window, insiders at IMVT bought $350.0M and sold $16.3M based on SEC Form 4 filings.
Can I get alerts for IMVT insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Immunovant, Inc. (IMVT). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Immunovant, Inc. is in the Healthcare sector.